Pharmacotherapy for acromegaly: future role for pasireotide?
Somatostatin receptor ligands (octreotide and lanreotide) are currently first-line pharmacotherapy for patients with acromegaly in whom surgery fails to control the disease or cannot be considered. The efficacy of a new pan somatostatin receptor ligand, pasireotide, has been investigated as a potential treatment of acromegaly. Several clinical trials showed disease-remission with pasireotide in one-third of patients and some octreotide-resistant patients were responsive to pasireotide. Pasireotide can likely be used for patients with suboptimal response or resistance to treatment with the approved maximal doses of octreotide long-acting release (LAR) or lanreotide Autogel; however, the development or exacerbation of diabetes mellitus is of concern.
Pituitary Center, Endocrinology, Diabetes and Metabolism Division, Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 3066, Los Angeles, CA 90048, USA. Electronic address: benshlomoa@cshs.org.
Anat
A
Ben-Shlomo
D000172:Acromegaly / Q000188:drug therapy*; D006728:Hormones / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D006728:Hormones; D013004:Somatostatin; C517782:pasireotide
Acromegaly; Pasireotide; Pharmacotherapy; Somatostatin receptor ligand